In April, the government of India called a halt to trials of the Human Papilloma Virus (HPV) vaccine. This came about because of a civil society-led investigation which highlighted serious ethical violations in at least one trial.
In India, civil society groups have long been voicing their concerns regarding the safety and efficacy of the two HPV vaccines, along with the aggressive promotion of the vaccines and the need to investigate reported deaths and adverse events post vaccination.
According to Economic and Political Weekly, the investigation that led to the ban highlights how:
"... the promotional practices of drug companies, pressure from powerful international organizations, and the co-option of, and uncritical endorsement by India's medical associations are influencing the country's public health priorities."
In the US, only about one third of eligible young U.S. women complete a full course of the vaccine against the human papillomavirus. The older the woman, the less likely she is to have gotten even one of the three doses.
A study looked at almost 10,000 women between the ages of 9 and 26 eligible for HPV vaccination. Of these, only 39.1 percent received a single dose, 30.1 percent received two doses, and 30.8 percent completed the three dose regimen.
According to Yahoo News:
"Women between the ages of 18 to 26 were least likely to get even a single dose, which ... was probably due to the influence of parents on younger women, since parental consent is required for getting the vaccine under age 18."